Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia.
Oral administration of CS-500, a competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, lowered the serum cholesterol level of both normal and WHHL-rabbits (the first example of heritable hyperlipidemic animals) at doses higher than 5 mg/kg/day. Phospholipids decreased concomitantly, whereas triglycerides did not in either normal or WHHL-rabbits.
D000818:Animals; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005502:Food; D006949:Hyperlipidemias / Q000188:drug therapy / Q000235:genetics*; D007009:Hypolipoproteinemias / Q000209:etiology*; D008148:Lovastatin / Q000031:analogs & derivatives*; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D010743:Phospholipids / Q000097:blood; D011817:Rabbits; D014280:Triglycerides / Q000097:blood
D009281:Naphthalenes; D010743:Phospholipids; D014280:Triglycerides; C012258:mevastatin; D002784:Cholesterol; D008148:Lovastatin